| Product Code: ETC8853931 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Ustekinumab, a biologic used in the treatment of autoimmune conditions like psoriasis and Crohns disease, is gradually gaining adoption in dermatology and gastroenterology practices. High costs and limited insurance coverage remain barriers, but demand is increasing among private-pay patients seeking advanced treatment options.
Used in chronic inflammatory diseases like psoriasis and Crohns, ustekinumab is gaining market share following expanded reimbursement and physician familiarity. Growth is supported by dermatology clinics and gastroenterology specialists offering advanced biologic therapies.
The ustekinumab market is hampered by the high cost of biologic therapies and restrictive insurance coverage. The lack of widespread diagnostic testing for autoimmune conditions delays patient identification and initiation of treatment. Also, biosimilar availability is limited, restricting cost-effective alternatives.
Ustekinumab, used in the treatment of psoriasis, Crohns disease, and ulcerative colitis, is gaining demand in the Philippines. Investors can capitalize by facilitating regulatory approvals, building partnerships with dermatology and gastroenterology clinics, and offering patient support programs to enhance access and adherence.
Ustekinumab, a biologic for psoriatic diseases and inflammatory bowel disease, requires FDA approval and pricing review under the Maximum Drug Retail Price (MDRP) program. The DOHs National Formulary Committee may include it for coverage through public hospital procurement. PhilHealth may reimburse eligible patients under specialty drug benefits, subject to clinical criteria.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Ustekinumab Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Ustekinumab Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Ustekinumab Market - Industry Life Cycle |
3.4 Philippines Ustekinumab Market - Porter's Five Forces |
3.5 Philippines Ustekinumab Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Philippines Ustekinumab Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Philippines Ustekinumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in the Philippines |
4.2.2 Growing awareness and adoption of advanced biologic treatments |
4.2.3 Favorable government policies and initiatives supporting healthcare access and affordability |
4.3 Market Restraints |
4.3.1 High cost associated with ustekinumab treatment |
4.3.2 Limited healthcare infrastructure and access in rural areas |
4.3.3 Competition from other biologic treatments in the market |
5 Philippines Ustekinumab Market Trends |
6 Philippines Ustekinumab Market, By Types |
6.1 Philippines Ustekinumab Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Ustekinumab Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Philippines Ustekinumab Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.1.4 Philippines Ustekinumab Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.2 Philippines Ustekinumab Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Philippines Ustekinumab Market Revenues & Volume, By Arthritis, 2021- 2031F |
6.2.3 Philippines Ustekinumab Market Revenues & Volume, By Colitis, 2021- 2031F |
6.2.4 Philippines Ustekinumab Market Revenues & Volume, By Lupus Erythematosus, 2021- 2031F |
6.2.5 Philippines Ustekinumab Market Revenues & Volume, By Myositis Multiplex With Palmoplantar Pustulosis, 2021- 2031F |
6.2.6 Philippines Ustekinumab Market Revenues & Volume, By Cirrhosis Of The Liver, 2021- 2031F |
6.2.7 Philippines Ustekinumab Market Revenues & Volume, By Sarcoidosis, 2021- 2031F |
6.2.8 Philippines Ustekinumab Market Revenues & Volume, By Other, 2021- 2031F |
6.2.9 Philippines Ustekinumab Market Revenues & Volume, By Other, 2021- 2031F |
7 Philippines Ustekinumab Market Import-Export Trade Statistics |
7.1 Philippines Ustekinumab Market Export to Major Countries |
7.2 Philippines Ustekinumab Market Imports from Major Countries |
8 Philippines Ustekinumab Market Key Performance Indicators |
8.1 Patient adherence rates to ustekinumab treatment |
8.2 Number of healthcare facilities offering ustekinumab treatment |
8.3 Rate of physician training and certification in prescribing ustekinumab |
9 Philippines Ustekinumab Market - Opportunity Assessment |
9.1 Philippines Ustekinumab Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Philippines Ustekinumab Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Philippines Ustekinumab Market - Competitive Landscape |
10.1 Philippines Ustekinumab Market Revenue Share, By Companies, 2024 |
10.2 Philippines Ustekinumab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here